Trial reportCardiovascular ultrasound2022
Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathy.
Trial report in Cardiovascular ultrasound, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02560467 (Perfusion Imaging With Myocardial Contrast Echocardiography in HCM), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Perfusion Imaging With Myocardial Contrast Echocardiography in HCM
Who cites it
16 citing papers in PubMed, 15 citations in OpenAlex.
- Primary versus iatrogenic (post-PCI) coronary microvascular dysfunction: a wire-based multimodal comparison.Open heart · 2023Trial
- Preliminary Exploration of Quantitative Stress Myocardial Contrast Echocardiography for Risk Stratification in Hypertrophic Cardiomyopathy: A 5-Year Prospective Study.Reviews in cardiovascular medicine · 2026Article
- Estrogen Deprivation During Primate (Papio anubis) Pregnancy: Impact on Systemic Microvascular Flow and Cardiovascular Development and Function After Birth in Offspring.Journal of medical primatology · 2026Article
- Quantitative Assessment of Myocardial Perfusion in Physiological and Pathological Hypertrophy Using Myocardial Contrast Echocardiography.Clinical cardiology · 2026Article
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
- Investigation of the cardioprotective potential of dantrolene in mitigating arsenic-induced cardiac dysfunction in rats.Acta biochimica et biophysica Sinica · 2025Article
- Myocardial Perfusion Imaging with Cardiovascular Magnetic Resonance in Nonischemic Cardiomyopathies: An In-Depth Review of Techniques and Clinical Applications.Medicina (Kaunas, Lithuania) · 2025Review
- Association between segmental noninvasive longitudinal strain and quantitative microvascular perfusion in ST-segment elevation myocardial infarction: implications for clinical outcomes.BMC cardiovascular disorders · 2025Article
- Low-dose dobutamine stress myocardial contrast echocardiography for evaluating myocardial microcirculation perfusion and predicting long-term prognosis in ST-segment elevation myocardial infarction after percutaneous coronary intervention.Journal of cardiothoracic surgery · 2025Article
- Emerging Imaging Techniques for Atherosclerosis in Systemic Immune-Mediated Inflammatory Conditions.Arteriosclerosis, thrombosis, and vascular biology · 2025Review
- Impaired longitudinal systolic-diastolic coupling and cardiac response to exercise in patients with hypertrophic cardiomyopathy.Echocardiography (Mount Kisco, N.Y.) · 2024Article
- Arsenic trioxide-induced cardiotoxicity: the protective effect of 2-aminoethoxydiphenyl-borate.Acta biochimica et biophysica Sinica · 2024Article
- The usefulness of contrast echocardiography in the evaluation of cardiac masses: a multicenter study.BMC cardiovascular disorders · 2024Article
- Enhancing Prediction of Myocardial Recovery After Coronary Revascularization: Integrating Radiomics from Myocardial Contrast Echocardiography with Machine Learning.International journal of general medicine · 2024Article
- Contrast Echocardiography for Assessing Myocardial Perfusion.Current cardiology reports · 2023Review
- Hypertrophic Cardiomyopathy Diagnosis and Treatment in High- and Low-Income Countries: A Narrative Review.Cureus · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPerfusion defects during stress can occur in hypertrophic cardiomyopathy (HCM) from either structural or functional abnormalities of the coronary microcirculation. In this study, vasodilator stress myocardial contrast echocardiography (MCE) was used to quantify and spatially characterize hyperemic myocardial blood flow (MBF) deficits in HCM.
methodsRegadenoson stress MCE was performed in patients with septal-variant HCM (n = 17) and healthy control subjects (n = 15). The presence and spatial distribution (transmural diffuse, patchy, subendocardial) of perfusion defects was determined by semiquantitative analysis. Kinetic analysis of time-intensity data was used to quantify MBF, microvascular flux rate (β), and microvascular blood volume. In patients undergoing septal myectomy (n = 3), MCE was repeated > 1 years after surgery.
resultsIn HCM subjects, perfusion defects during stress occurred in the septum in 80%, and in non-hypertrophied regions in 40%. The majority of septal defects (83%) were patchy or subendocardial, while 67% of non-hypertrophied defects were transmural and diffuse. On quantitative analysis, hyperemic MBF was approximately 50% lower (p < 0.001) in the hypertrophied and non-hypertrophied regions of those with HCM compared to controls, largely based on an inability to augment β, although hypertrophic regions also had blood volume deficits. There was no correlation between hyperemic MBF and either percent fibrosis on magnetic resonance imaging or outflow gradient, yet those with higher degrees of fibrosis (≥ 5%) or severe gradients all had low septal MBF during regadenoson. Substantial improvement in hyperemic MBF was observed in two of the three subjects undergoing myectomy, both of whom had severe pre-surgical outflow gradients at rest.
conclusionPerfusion defects on vasodilator MCE are common in HCM, particularly in those with extensive fibrosis, but have a different spatial pattern for the hypertrophied and non-hypertrophied segments, likely reflecting different contributions of functional and structural abnormalities. Improvement in hyperemic perfusion is possible in those undergoing septal myectomy to relieve obstruction.
trial registrationClinicalTrials.gov NCT02560467.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.